Nature Technology Corporation (United States)
- Research works
- 26 ▼ 81% vs 2013–17
- Citations
- 1.2k 45.1 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 47% world 28%
Not ranked overall: Nature Technology Corporation (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at Nature Technology Corporation (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Gene Therapy, Genomics, Metagenomics, Virus, Bacteriophage, Ecology, Genomic Integration and Pathogenesis.
- Tumor Regression
- Recombinant Protein
- Glycosylation
- siRNA Delivery
- RNA-Guided
- Gene Regulation
- Biopharmaceutical Production
- Norovirus
- Viral Vectors
- Vaccine
- Genomic Integration
- Ecology
- Virus
- Genomics
- Gene Therapy
- Metagenomics
- Bacteriophage
- Epidemiology
- Pathogenesis
- AAV
- Infection
- Rotavirus
- Bacterial Physiology
- Genome Engineering
- RNA Interference
- Immunotherapy
- Mammalian Cells
- Bacterial Therapy
- Tumor Targeting
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 29 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 29 words, with their numbers
- Gene Therapy6▲ 85×3 topics
- Genomics5▲ 52×3 topics
- Metagenomics5▲ 143×2 topics
- Virus4▲ 145×2 topics
- Bacteriophage4▲ 251×1 topic
- Ecology4▲ 81×1 topic
- Epidemiology4▲ 4.0×9 topics
- Genomic Integration4▲ 148×2 topics
- Pathogenesis3▲ 23×6 topics
- Vaccine3▲ 31×5 topics
- AAV3▲ 178×1 topic
- Viral Vectors3▲ 178×1 topic
- Infection3▲ 40×2 topics
- Norovirus2▲ 161×1 topic
- Rotavirus2▲ 161×1 topic
- Biopharmaceutical Production2▲ 108×2 topics
- Bacterial Physiology2▲ 161×1 topic
- Gene Regulation2▲ 53×1 topic
- Genome Engineering2▲ 132×1 topic
- RNA-Guided2▲ 132×1 topic
- RNA Interference2▲ 63×1 topic
- siRNA Delivery2▲ 94×1 topic
- Immunotherapy2▲ 9.3×4 topics
- Glycosylation1▲ 23×2 topics
- Mammalian Cells1▲ 119×1 topic
- Recombinant Protein1▲ 119×1 topic
- Bacterial Therapy1▲ 89×1 topic
- Tumor Regression1▲ 46×2 topics
- Tumor Targeting1▲ 29×1 topic
Which research topics does Nature Technology Corporation (United States) publish most on?
By volume in 2022–2025: RNA Interference and Gene Delivery, CRISPR and Genetic Engineering, Virus-based gene therapy research and T-cell and B-cell Immunology.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 RNA Interference and Gene Delivery Molecular Biology 0 works
- 2 CRISPR and Genetic Engineering Molecular Biology 0 works
- 3 Virus-based gene therapy research Genetics 0 works
- 4 T-cell and B-cell Immunology Immunology 0 works
- 5 CAR-T cell therapy research Oncology 0 works
- 6 Immune Cell Function and Interaction Immunology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Nature Technology Corporation (United States)'s research output changed?
Output in 2018–2022 was 81% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Lincoln
- University of Nebraska–Lincoln
- Entrepreneurial Ecosystems
- University of Nebraska System
- Pacific Engineering (United States)
- Nebraska Wesleyan University
- Nebraska Hematology-Oncology
- Nebraska Game and Parks Commission
- Bryan Health
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.